MHRA-101053-PIP01-23-M01 (update)

Key Facts

Active Substance
  • DOLUTEGRAVIR
  • ABACAVIR
  • LAMIVUDINE
Invented Name
  • TRIUMEQ
  • TRIUMEQ
PIP Number MHRA-101053-PIP01-23-M01 (update)
Pharmaceutical form(s)
  • Film-coated tablet
  • Dispersible tablet
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance opinion date
16/01/2024
Compliance Check Procedure Number
Compliance procedure number
MHRA-101053-PIP01-23-M01-C

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):DOLUTEGRAVIRABACAVIRLAMIVUDINE.pdf
Published Date 30/01/2024